Published in Medical Letter on the CDC and FDA, April 22nd, 2001
Patients with hemophilia lack certain clotting factors in the blood, but those factors can be replaced with the use of commercially manufactured blood products. Before 1990, testing procedures for donor blood were not as sensitive for detecting hepatitis viruses as they are now, meaning patients receiving those blood products before 1990 are at a greater risk for developing viral infections.
J. Michael C....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.